Related Experiment Videos
Recombinant erythropoietin for prevention of anemia in preterm infants
1Department of Neonatology, Virchow University Hospital, Berlin, Fed. Rep. of Germany.
Insights
Recombinant erythropoietin (rhEPO) effectively reduced transfusions in preterm infants by 18%. Optimal rhEPO dosage is 300-1200 IU/kg weekly, with no observed adverse effects.
Area of Science:
- Neonatology
- Hematology
- Pharmacology
Background:
- Anemia of prematurity is a common complication in preterm infants.
- Early interventions are crucial to prevent or treat this condition.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant erythropoietin (rhEPO) in preventing and treating anemia of prematurity.
- To determine optimal rhEPO dosage ranges and assess its impact on transfusion rates.
Main Methods:
- Meta-analysis of eight controlled trials involving over 800 preterm infants.
- Assessment of rhEPO dosage (300-1200 IU/kg/week) and its effect on transfusion requirements.
- Monitoring for adverse events and impact on granulopoiesis and platelet formation.
Main Results:
- A statistically significant 18% reduction in transfused infants was observed with rhEPO treatment.
- Effective rhEPO dosage ranged from 300 to 1200 IU/kg per week.
- No adverse events or negative effects on blood cell formation were attributed to rhEPO.
Conclusions:
- rhEPO treatment is a valuable component in managing anemia of prematurity.
- Its preventive effect is limited in extremely premature or critically ill infants during the first two weeks of life.
- A comprehensive approach including placental transfusion, minimized blood sampling, and nutritional support is recommended alongside rhEPO.
Abstract:
In order to prevent or to treat anemia of prematurity, more than 800 preterm infants were enrolled into controlled studies with recombinant erythropoietin (rhEPO) during the past five years. The effective dosage seems to be within the range of 300 to 1200 IU/kg per week, markedly higher than in adults or children with anemia due to renal failure. No adverse events nor impairment of granulopoiesis or platelet formation could be attributed to erythropoietin. Statistical metaanalysis of eight controlled trials revealed an 18% reduction of transfused infants. The preventive effect was scarce in very small and very sick preterm infants, and during the first two weeks of life, when hemorrhagic anemia due to diagnostic blood loss is predominant. rhEPO treatment is one step in the concept to prevent anemia of prematurity. This concept should also include placental transfusion, minimizing of diagnostic sampling, miniaturized laboratory tests, adequate iron supplementation, and optimal nutritive protein administration.